# From GAP to opportunity













## From gap to opportunity

How the PharmaNL gap analysis can support innovation

## Core partners

- Pivot Park Brigitte Drees
- Campus Groningen Ton Vries
- Universiteit Leiden Hubertus Irth
- Supported by FAST Benien Vingerhoed

Developed in cooperation with the Ministry of VWS, and submitted by VWS, with support from EZK, to the National Growth Fund (2nd round).



### **Marieke Meulemans**

Programme manager PharmaNL

## Why? Growth and earning potential underutilized

The growth potential and earning potential of the Dutch Life Sciences sector is currently not effectively used.



#### Infrastructure


Insufficient availability of easily accessible highquality infrastructure for development of promising innovative pharmaceutical products and production technologies



#### **Human Capital**


Shortage of properly qualified personnel to deliver these new pharmaceutical products and to exploit production technologies on Dutch soil.

## 2 PharmaNL programmes



- Euro 78,8 mio period 2024-2032
- To give a a sustainable boost to benefit from the economic potential of innovative pharmaceutical products and product technologies
- To improve the size and quality of the sector
- To improve the attractiveness of the sector for pharma and biotech companies

## Roles and responsibilities



Assesment of the applications

Distributing the funds via the calls


# PharmaNL | infrastructure

### **Objective SDI Programme**

to make available high-quality and innovative infrastructure facilities that are essential for groundbreaking pharmaceutical product and production technology developments in areas in which the Netherlands has a strong starting position, and for which the required R&D facilities and services are not available and/or will not be established under regular market forces.

# PharmaNL - Shared Development Infrastructure







https://www.zonmw.nl/nl/programma/pharmanl

Het PharmaNL Shared Development Infrastructure (SDI) programma richt zich op het opzetten van geavanceerde infrastructuur voor gedeeld gebruik door farmaceutische start-ups, scale-ups en academische onderzoeksgroepen.

# PharmaNL | human capital

### **Objective HCG Programme**

to train sufficient suitably qualified personnel (5000) for the Dutch pharmaceutical value chain. Through strengthening cooperation between industry and educational institutions, enabling a demand driven setup of education on post-MBO, -HBO and -Academic level. And resulting in high-quality hybrid and life-long-learning opportunities.





### **PharmaNL - Human Capital Growth**



Het PharmaNL Human Capital Growth (HCG) programma richt zich specifiek op het realiseren van een vraaggestuurde groei van het aantal personen dat een PharmaNL opleiding of PharmaNL onderwijs zal volgen.







## Projecten van start binnen PharmaNL Human Capital Growth



CALL 2023-1



Update 30 april, 2024

'Life-long learning programma voor post-graduate biomedische en farmaceutische professionals' Leiden University Medical Center

**'Early Drug Discovery Education Track'**HAN, RadboudUniversity Nijmegen, Pivot Park en Elevate

'Groningen Human Capital for Life Sciences'
LIFE Cooperative, Hanzehogeschool Groningen en het UMCG





#### Requirements

- ZonMw General Grant Provisions
  - State aid rules



- •Call 1 on invitation ~ €20 mln (in assessment)
- •Call 2 starts in 2025
- •Call 3 starts in 2026
- •Call 4 starts in 2027



€ 37 mIn

Max € 5 mln subsidy per SDI grant application ~ 50% subsidy (AGVV)


- •Call 1 on invitation ~ € 3.1 mln
- •Call 2 starts Q4 2024 ~ €5.9 mln
- •Call 3 starts in 2026/27 ~ €5.9 mln

Max € 1 mln subsidy per HCG grant application ~ 50% subsidy (AGVV)



gap analysis

## Demand driven: from input to impact








## **Drug development proces**

Drug Discovery, Development, and Deployment Map Wagner et al.

g

167



**Figure 1** Therapeutic development chevron diagram. Traditional chevron diagram representation of therapeutic development. Colors in this chevron correspond to the associated "neighborhoods" on the Drug Discovery, Development, and Deployment Map. FDA, US Food and Drug Administration.


## 4D Map

- The Drug Discovery, Development, and Deployment Map (4DM)
- Developed in 2017 by The Forum on Drug Discovery, Development, and Translation of the US National Academies of Sciences, Engineering, and Medicine in the US
- Published in Nature Reviews Drug Discovery
- A dynamic map for learning, communicating, navigating and improving therapeutic development




Figure 1 Therapeutic development chevron diagram. Traditional chevron diagram representation of therapeutic development. Colors in this chevron correspond to the associated "neighborhoods" on the Drug Discovery, Development, and Deployment Map. FDA, US Food and Drug Administration.

https://www.nature.com/articles/nrd.2017.217




## From map to questionnaire tool


4D Map Small Molecule & Biologics
Development



#### Questionnaire





#### Sustainable gap-analysis tool



# Sample size: organisations interviewed

- Current sample : 71 organisations\*
- 2023/24 Groningen / Campus Groningen, Leiden / Leiden BioScience Park and Pivot Park.
- From 2024 adding other pharmaceutical hubs





**71** organisations interviewed\*

\*status May 17, 2024


## Types of organisations interviewed




CRO	(both preclinical and lab services and clinical trial services)
CDMO	Support pharmaceutical and biotechnology organizations with formulation and production of the developed products
PRODUCT DEVELOPMENT	Institutions, pharmaceutical and biotechnological organizations developing a therapeutic product
EDUCATION	Educational institutions (universities, HBO, MBO)
SUPPORTING PHARMA SERVICES	Provide indirect support to pharmaceutical and biotechnology organizations, e.g. recruitment and legal services.

## **Data management**

#### Standardized method of documenting current and required infrastructure & skills




infrastructure




skills

# PharmaNL | infrastructure

## Data dashboard - SDI



## **Dashboard - SDI**



#### Towards sustainable discovery and production of new therapies

Trend?	yes
In scope of other growthfund project like Biotech Booster, Oncode Accelerator, RegMedXB, CPBT?	no
Substantiated by GAP analysis?	HCG & SDI
Already part of a PharmaNL project?	Possibly
Which domains?	A, B, C, D, E, I
Programme line	HCG & SDI

Early discovery infrastructure

HCG: #assay development #AI #robotics #automated lab

SDI: NMR, High content /Cell imaging, HTS, Flow cytometry, Microscope, SEM, Mass Spectrometry, HPLC/LC-MS/UPLC/GC-MS, Surface Plasmon Resonance, PCR, FACS

PharmaNL predefined criteria including those from NGF en ZonMw

Shared Development Infrastructure

**Human Capital** 

#### Towards sustainable discovery and production of new therapies

Trend?	yes
In scope of other growthfund project like Biotech Booster, Oncode Accelerator, RegMedXB, CPBT?	no
Substantiated by GAP analysis?	HCG & SDI
Already part of a PharmaNL project?	nee
Which domains?	D, I
Programme line	HCG & SDI

Small scale (shared) manufacturing facilities

HCG: # cleanroom / gowning procedure #personalized medicine #production #aseptic #GMP procedures #manufacturing #continuousmanufacturing

SDI: Small Scale GMP cleanroom, GMP (protein) production; shared GMP cleanroom radiation regulated production facility


PharmaNL predefined criteria including those from NGF en ZonMw

Shared Development Infrastructure

**Human Capital** 

# PharmaNL | human capital

## From skills to themes & trends




Examples required skills

Project management, communication skills


F. Regulatory review

G. Postmarketing


H. Medical landscape



# **Heatmap-HCG**



## **Analysis - HCG**



## Some high level results

MBO trained personnel largely working in domain I (Commercial Manufacturing), somewhat in D1 and D2 (In vivo + GLP preclinical + manufacturing)

High demand for (MBO) trained operators in the coming years.

Shift in required skills for MBO educated personnel due to digitization and automation

HBO,WO and PHD educated personnel mostly working in the same process steps A, B, C, D

**HBO,WO and PHD** educated staff mostly working in the same teams, with different responsibilities

More interviews to be done for an inventory of requirements in domains E, F,G,H (clinical, regulatory, post marketing, medical landscape)

#### Towards sustainable discovery and production of new therapies

Trend?	yes
In scope of other growthfund project like Biotech Booster, Oncode Accelerator, RegMedXB, CPBT?	no
Substantiated by GAP analysis?	HCG
Already part of a PharmaNL project?	no
Which domains?	I
Programme line	HCG

Automation production & warehousing

HCG: MBO staff working in production / warehousing need to become more knowledgeable about automation of the production process and work differently.

SDI: Continuous production, refer to GMP cleanrooms

PharmaNL predefined criteria including those from NGF en ZonMw

Shared Development Infrastructure

**Human Capital** 

#### Towards sustainable discovery and production of new therapies

#### Artificial Intelligence

Trend?	yes
In scope of other growthfund project like Biotech Booster, Oncode Accelerator, RegMedXB, CPBT?	yes: infrastructure for AI
Substantiated by GAP analysis?	HCG & SDI
Already part of a PharmaNL project?	no
Which domains?	A,B, C, D, E, I
Programme line	HCG

# computational life sciences #ai #artificial intelligence

PharmaNL predefined criteria including those from NGF en ZonMw

Shared Development Infrastructure

**Human Capital** 

## **Next steps**







More information?

